SynthesisSultan Qaboos University medical journal2025
The Efficacy of Topical Paromomycin-Gentamicin versus Topical Paromomycin Alone in The Treatment of Cutaneous Leishmaniasis: A meta-analysis of randomized controlled trials.
Synthesis in Sultan Qaboos University medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous leishmaniasis (CL) is the most common protozoal skin infection worldwide. Multiple treatments for CL have been developed to address issues related to resistance, availability, and safety. Topical treatments have shown promise by reducing unnecessary systemic exposure and providing a viable local therapeutic option. A systematic review and meta-analysis were conducted of all literature published before 28 February 2025 through PubMed/MEDLINE, the Cochrane Library, and EBSCO, comparing topical paromomycin-gentamicin (PG) with topical paromomycin alone (PR). Two studies involving a total of 774 patients were included. Relative risks (RRs) from both studies were pooled using a fixed-effect meta-analysis. The meta-analysis showed no significant difference in the final clinical cure of the index lesion between PG and PR (RR = 1.030; 95% confidence interval [CI]: 0.950-1.117), nor in the rate of cure of all lesions (RR = 0.987; 95% CI: 0.909-1.072). No serious adverse events were reported. When treating CL topically, the addition of gentamicin to paromomycin does not confer additional benefit.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.